Section 6(b) of the Act on July 15, 2009 (74 FR 34364).

The last notification was filed with the Department on July 13, 2010. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on August 18, 2010 (75 FR 51114).

Patricia A. Brink,

Deputy Director of Operations, Antitrust Division.

[FR Doc. 2010–26740 Filed 10–25–10; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—International SAE Consortium Ltd.

Notice is hereby given that, on September 21, 2010, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), International SAE Consortium Ltd. ("ISAEC") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Amgen, Inc., Thousand Oaks, CA; AstraZeneca UK Ltd., London, United Kingdom; Cerner Corporation, Kansas City, MO; Clinical Data, Inc., Newton, MA; and Merck Sharp & Dohme Corp., Rahway, NJ, has been added as parties to this venture.

Also, F. Hoffmann-La Roche, INC., Basel, Switzerland; Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ; and Sanofi-Aventis, Bridgewater, NJ, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and ISAEC intends to file additional written notification disclosing all changes in membership.

On September 27, 2007, ISAEC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on November 7, 2007 (72 FR 62867).

The last notification was filed with the Department of Justice on May 21, 2008. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on June 27, 2008 (73 FR 36571).

Patricia A. Brink,

Deputy Director of Operations, Antitrust Division.

[FR Doc. 2010–26737 Filed 10–25–10; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—ASTM International

Notice is hereby given that, on September 23, 2010, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), ASTM International ("ASTM") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing additions or changes to its standards development activities. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, ASTM has provided an updated list of current, ongoing ASTM standards activities originating between May 2010 and September 2010 designated as work items. A complete listing of ASTM work items, along with a brief description of each, is available at *http://www.astm.org.*

On September 15, 2004, ASTM filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on November 10, 2004 (69 FR 65226).

The last notification was filed with the Department on May 6, 2010. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on June 1, 2010 (75 FR 30440).

Patricia A. Brink,

Deputy Director of Operations, Antitrust Division.

[FR Doc. 2010–26736 Filed 10–25–10; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Alliance for Water Stewardship

Notice is hereby given that, on September 10, 2010, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 e*t seq.* ("the Act"), Alliance for Water Stewardship ("AWS") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the name and principal place of business of the standards development organization and (2) the nature and scope of its standards development activities. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the name and principal place of business of the standards development organization is: Alliance for Water Stewardship, Arlington, VA. The nature and scope of AWS's standards development activities are: (1) To establish equitable, voluntary, transparent, science-based standards for socially beneficial and environmentally sustainable use and management of fresh water at the watershed level; (2) to promote use and management of fresh water which will maintain or improve biodiversity and ecological processes and secure longterm benefits for local peoples and society at large; and (3) to encourage effective governance for water use and management through voluntary certification of businesses and water service providers. The AWS is responsible for coordinating and overseeing the process of developing water use and management target standards and indicators, such as catchment flow volume, user abstraction, nutrients in effluents, sediments in effluents, temperature of effluents, water pricing, and other aspects of a voluntary water stewardship standard system. As part of its standards development activities, the AWS organizes a Global Water Roundtable and continent-level Regional Initiatives, through which it invites stakeholder organizations to participate in the standards development process. The AWS will hold the intellectual property resulting from its standards development activities until such a time when it may

transfer its holdings to a successor organization or is itself designated the permanent custodian of the intellectual property.

Below is the name and contact information of an individual from whom additional information concerning the organization can be obtained: Carey R. Ramos, Esq.; Paul, Weiss, Rifkind, Wharton & Garrison LLP; 1285 Avenue of the Americas; New York, NY 10019–6064.

Patricia A. Brink,

Deputy Director of Operations, Antitrust Division.

[FR Doc. 2010–26734 Filed 10–25–10; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;Notice of Application

This is notice that on July 22, 2010, Cody Laboratories Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414–9321, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Raw Opium (9600)	II
Concentrate of Poppy Straw (9670).	II

The company plans to import narcotic raw materials for manufacturing and further distribution to its customers. The company is registered with DEA as a manufacturer of several controlled substances that are manufactured from raw opium, poppy straw, and concentrate of poppy straw.

As explained in the Correction to Notice of Application pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for hearings on applications to import narcotic raw material are not appropriate.

As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: October 19, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator,Office of Diversion Control,Drug Enforcement Administration.

[FR Doc. 2010–27023 Filed 10–25–10; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on July 12, 2010, Noramco, Inc., Division of Ortho-McNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Raw Opium (9600)	II
Concentrate of Poppy Straw (9670).	II
Tapentadol (9780)	II

The company plans to import the Raw Opium (9600) and Concentrate of Poppy Straw (9670) to manufacture other controlled substances. The company plans to import Tapentadol (9780) in intermediate form for the bulk manufacture of Tapentadol (9780) which it will distribute to its customers.

No comments, objections, or requests for any hearings will be accepted on any application for registration or re-registration to import crude opium, poppy straw, concentrate of poppy straw, and coca leaves. As explained in the Correction to Notice of Application pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for hearings on applications to import narcotic raw material are not appropriate.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act [21 U.S.C. 952(a)(2)(B)] may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 26, 2010.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: October 19, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator,Office of Diversion Control,Drug Enforcement Administration.

[FR Doc. 2010–27025 Filed 10–25–10; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 12 2010, Aldrich Chemical Company Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio 45342–4304, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Gamma Hydroxybutyric Acid (2010).	I
Methaqualone (2565)	I
Ibogaine (7260)	I
Tetrahydrocannabinols (7370)	I
2,5–Dimethoxyamphetamine (7396).	I
Psilocyn (7438)	I
Normorphine (9313)	I
Acetylmethadol (9601)	I
Alphacetylmethadol except levo–alphacetylmethadol (9603).	I
Normethadone (9635)	I
Norpipanone (9636)	I
3–Methylfentanyl (9813)	I